<p>Initial induction chemotherapy to eradicate the bulk of acute myeloid leukemia (AML) cells results in complete remission (CR) in the majority of patients. However, leukemic cells persisting in the bone marrow below the morphologic threshold remain unaffected and have the potential to proliferate and re‐emerge as AML relapse. Detection of minimal/measurable residual disease (MRD) is a promising prognostic marker for AML relapse as it can assess an individual patients’ risk profile and evaluate their response to treatment. With the emergence of molecular techniques, such as next generation sequencing (NGS), a more sensitive assessment of molecular MRD markers is available. In recent years, the detection of MRD by molecular assays and its association with AML relapse and survival has been explored and verified in multiple studies. Although most studies show that the presence of MRD leads to a worse clinical outcome, molecular‐based methods face several challenges including limited sensitivity/specificity, and a difficult distinction between mutations that are representative of AML rather than clonal hematopoiesis. This review describes the studies that have been performed using molecular‐based assays for MRD detection in the context of other MRD detection approaches in AML, and discusses limitations, challenges and opportunities.</p>

doi.org/10.3390/cancers13215431, hdl.handle.net/1765/137122
Cancers
Erasmus MC: University Medical Center Rotterdam

C.M. (Christian) Vonk, ASA (Adil) Al Hinai, D.W. (Diana) Hanekamp, & P (Peter) de Valk. (2021). Molecular minimal residual disease detection in acute myeloid leukemia. Cancers (Vol. 13). doi:10.3390/cancers13215431